Department of Urology, Queen's University, Kingston, Ontario, Canada.
Eur Urol. 2011 Sep;60(3):578-84. doi: 10.1016/j.eururo.2011.06.021. Epub 2011 Jun 24.
Percutaneous needle core biopsy has become established in the management of small renal masses ≤ 4 cm (SRMs). Recent series have reported success rates of ≥ 80%. Nondiagnostic results continue to be problematic.
To determine the results of SRM biopsy and the outcomes of nondiagnostic biopsy and repeat biopsy.
DESIGN, SETTING, AND PARTICIPANTS: Patients undergoing renal tumor biopsy (RTB) for suspected renal cell carcinoma (RCC) were included in a prospectively maintained database.
The database was analyzed retrospectively to determine the pathology and outcomes of SRM biopsy. Outcomes of patients with nondiagnostic biopsy were determined. Patients undergoing repeat biopsy were identified and their outcomes analyzed.
Three hundred forty-five biopsies were performed (mean diameter: 2.5 cm). Biopsy was diagnostic in 278 cases (80.6%) and nondiagnostic in 67 cases (19.4%). Among diagnostic biopsies, 221 (79.4%) were malignant, 94.1% of which were RCC. Histologic subtyping and grading of RCC was possible in 88.0% and 63.5% of cases, respectively. Repeat biopsy was performed in 12 of the 67 nondiagnostic cases, and a diagnosis was possible in 10 (83.3%). Eight lesions were malignant and two were oncocytic neoplasms. Pathology was available for 15 masses after initial nondiagnostic biopsy; 11 (73%) were malignant. Larger tumor size and a solid nature on imaging predicted a successful biopsy on multivariate analysis. Grade 1 complications were experienced in 10.1% of cases, with no major bleeding and no seeding of the biopsy tract. There was one grade 3a complication (0.3%). This is a retrospective study and some data are unavailable on factors that may affect biopsy success rates. Repeat biopsy was not standard practice prior to this analysis.
RTB can be performed safely and accurately in the investigation of renal masses ≤ 4 cm. A nondiagnostic biopsy should not be considered a surrogate for the absence of malignancy. Repeat biopsy can be performed with similar accuracy, providing a diagnosis for most patients.
经皮穿刺芯活检已成为管理≤4cm 小肾肿瘤(SRM)的标准方法。最近的系列报道成功率≥80%。非诊断性结果仍然是个问题。
确定 SRM 活检的结果,以及非诊断性活检和重复活检的结果。
设计、地点和参与者:纳入了一项前瞻性维护的数据库中接受肾肿瘤活检(RTB)以怀疑肾细胞癌(RCC)的患者。
对数据库进行回顾性分析,以确定 SRM 活检的病理结果和结果。确定了非诊断性活检患者的结局。确定了接受重复活检的患者,并分析了他们的结局。
共进行了 345 次活检(平均直径 2.5cm)。278 例(80.6%)活检诊断为阳性,67 例(19.4%)活检诊断为阴性。在诊断性活检中,221 例(79.4%)为恶性,其中 94.1%为 RCC。RCC 的组织学亚型和分级分别在 88.0%和 63.5%的病例中得到了明确。在 67 例非诊断性活检中,有 12 例进行了重复活检,其中 10 例(83.3%)得到了诊断。8 个病灶为恶性,2 个为嗜酸细胞瘤。在最初非诊断性活检后,有 15 个肿块获得了病理学结果;11 个(73%)为恶性。肿瘤较大和影像学上呈实性是多变量分析中活检成功的预测因素。10.1%的病例出现 1 级并发症,无重大出血,活检通道无种植。有 1 例 3a 级并发症(0.3%)。这是一项回顾性研究,一些可能影响活检成功率的因素的数据不可用。在这项分析之前,重复活检不是标准做法。
RTB 可以安全、准确地用于≤4cm 肾肿块的检查。非诊断性活检不应被视为无恶性肿瘤的替代方法。重复活检可以以类似的准确性进行,为大多数患者提供诊断。